Clinical science

Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study

Haner Direskeneli1,*, Omer Karadag2, Askin Ates3, Abdurrahman Tufan4, Nevsun Inanc1, Serdar S. Koça5, Gozde Y. Cetin6, Servet Akar7, Muhammet Cinar8, Sedat Yilmaz9, Neslihan Yilmaz9, Ediz Dalkilic10, Cemal Bas11, Baris Yilmazer12, Ali Sahin13, Duygu Ersözlu14, Mehmet E. Tezcan15, Nesrin Sen15, Gokhan Keser16, Umut Kalyoncu12,2, Berkan Armagan12,2, Basak Hacibedel17, Kerem Helvacioglu17, Teoman Y. Cesur17, Canberk S. Basibuyuk17, Serdar Alkan17, Levent Mert Gunay17

1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey
2Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey
3Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey
4Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
5Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, Turkey
6Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
7Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University, Izmir, Turkey
8Clinic of Rheumatology, Gulhane Faculty of Medicine, Gulhane Training and Research Hospital, Health Science University, Ankara, Turkey
9Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, TC Demiroglu Bilim University, Istanbul, Turkey
10Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uludag University, Bursa, Turkey
11Clinic of Rheumatology, Department of Internal Medicine, Istanbul Provincial Health Directorate, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
12Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Trakya University, Edirne, Turkey
13Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey
14Clinic of Rheumatology, Department of Internal Medicine, SBU Adana City Training and Research Hospital, Adana, Turkey
15Division of Rheumatology, Department of Internal Medicine, Istanbul Provincial Health Directorate, Istanbul Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey
16Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ege University, Izmir, Turkey
17Pfizer Turkey, Istanbul, Turkey

*Correspondence to: Haner Direskeneli, Faculty of Medicine Hospital, Marmara University, Fevzi Çakmak, Muhsin Yazıcıoğlu Cd No. 10, 34899 Pendik/Istanbul, Turkey. E-mail: hanerdireskeneli@gmail.com

Abstract

Objective: We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences.

Methods: A multicentre, prospective, observational and 1-year follow-up study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms. DAS in 28 joints with ESR (DAS28-4(ESR)), EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (COR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments.

Results: Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final study visit at 12 months, and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated ($r < 0.001$). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and COR-19 scores at baseline.

Conclusion: The oral route was more frequently preferred by patients compared with physicians, although patients’ preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA.

Received: 10 November 2021; Accepted: 10 July 2022
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

RA is a chronic, systemic, disabling autoimmune disease and the most common form of inflammatory arthritis that causes functional disability, significant pain, joint destruction and premature mortality [1, 2]. The global prevalence of RA is estimated to be 0.24% [3], and prevalence in Turkey was found to be 0.36% [4]. Clinical remission and low disease activity are the main therapeutic goals of RA management. The conventional synthetic (cs) DMARDs continue to be recommended as the first-line treatment of RA, whereas biological (b) and targeted synthetic (ts) DMARDs (advanced RA treatments) are used, with or without csDMARDs, in patients who fail their initial treatment [5, 6]. When remission is not achieved, disease progression is characterized by progressive cartilage and bone damage and pain, leading to significant work disability, deterioration of quality of life (QoL), morbidity and mortality [7–10]. Despite conventional treatments, RA still has many deleterious consequences. From the patients’ perspective, these include persistent pain, functional disability, fatigue and depression, modified by health beliefs and underlying psychological problems. Treatment with DMARDs and biologic agents improves pain, fatigue and disability. DMARDs and biologics both significantly reduce HAQ scores, and the reduction is usually maintained for 2–5 years. This improvement is observed in both early and advanced stages of the disease [8]. Frequent assessment of disease activity and response to therapy is crucial for successful long-term management of RA [2].

Given the high disease burden of RA, consideration of patient preferences and medication adherence are crucial for sustained disease control [11]. Patient-reported issues of QoL and disability, however, are consistently reported to be topics of infrequent discussion during clinical follow-up visits [12, 13]. Patient adherence to advanced RA treatments has also been identified as a research question by the EULAR [5].

Assessment of patient preferences in treatment decisions of RA has gained popularity during the last decades [14]. Patient-centred care is thought to cause significant increases in patient satisfaction and treatment adherence levels [15–17]. An increased level of dialogue between RA patients and their physicians also optimizes the management of RA [18, 19]. Previous studies reported variable results regarding patient preferences and choice of medications. Medication efficacy, safety, route of medication administration (RoA), the cost-sharing or the routes for the financial provisions are among the essential factors in this decision-making process [14, 18, 20–23]. The differences associated with geographical place, culture and lifestyle in patient preferences can also lead to significant considerations for the individualized treatment of RA patients [18, 24]. However, overall perceptions of RA patients about their treatment options have been assessed in a limited number of studies [23].

Continuing a previous local study on patient-reported preferences, RoA and unmet needs in advanced RA management [25], we conducted a study to investigate QoL, disease activity, preferences for the RoA, productivity loss, and the compliance of patients treated with advanced RA medications to explore factors related to patient-reported outcomes and the management approach in routine practice.

We hypothesized that patient preferences might be impacted by both patient- and treatment-related factors. In this study, we aimed to examine the association between patient preferences regarding the RoA stratification and the patient-reported clinical outcomes after the use of advanced treatment modalities for RA.

Key messages

- Choices of RA patients and physicians differ for the preferred route of administration of advanced medications.
- Compliance worsens over time, regardless of patient and physician preferences for the route of administration.
- Advanced RA treatments improve quality of life, disease activity, health status and productivity in Turkish patients.

Lay Summary

What does this mean for patients?

People with rheumatoid arthritis (RA) and their physicians can have different views throughout the patient journey, whether deciding the main treatment objective, switching a drug or deciding the route of drug administration. However, data are limited in this area. For this purpose, we have conducted a survey study to identify differences between the views of patients and physicians on the management of RA. In this study, we have shown that RA medication compliance decreases over time, irrespective of medication route. This is similar to other studies. We also spotted that there are different routes of drug administration (RoA) preferred: a higher proportion of patients preferred an oral RoA compared with physicians (53.6% vs 31.4%, respectively). Patient and physician RoA preferences were not related to gender, age, disease duration, treatment type and disease activity. By surveying patients and physicians at the same time, we have identified their differences better compared with previous studies. Patient preferences should have a major impact on disease management, and the results of this study might encourage patients to discuss their thoughts and preferences with their clinicians to achieve a better outcome.

Keywords: RA, quality of life, patient preference, DAS, ESR, switch, advanced treatment

Methods

Study design and patients

This study was designed as a 1-year follow-up, national, multicentre, prospective and observational study, which was conducted between August 2015 and January 2020 in 17 study centres. Eligible patients were Turkish citizens ≥18 years of age, with a diagnosis of RA confirmed according to the ACR/EULAR 2010 criteria [26]. Patients could be switching between advanced RA treatments or receiving an advanced RA treatment for the first time at enrolment. Exclusion criteria were cognitive impairment that could prevent study assessments via questionnaires, participation in a clinical trial within the last 4 weeks or within the time frame of five times the half-life of a trial medication, employment with study institutions or the sponsor, and pregnancy or lactation for female subjects. To prevent bias, all available and reimbursed advanced RA treatment options in Turkey

[bDMARDs
Quality of life and patient preferences in RA

(adalimumab, etanercept, golimumab, infliximab, certolizumab, abatacept, rituximab, and tocilizumab) and tsDMARDs (tocafitinib)] were eligible. The approvals were obtained from Marmara University School of Medicine Clinical Research Ethical Committee (protocol no. A39212770/04.11.2016) and the Ministry of Health before the study commencement, and patients (or their legal representatives, if needed) signed informed consent (20.09.2016/V3) for study participation. A decision to initiate or change advanced RA treatment was not taken solely for the inclusion of participants in this study. The observational nature of the study in a real-world setting was protected.

Objectives and assessments

The primary objective of the study was to evaluate QoL and disease activity using DAS in 28 joints with ESR [DAS28-4(ESR)] over a 1-year period after initiation of advanced RA treatment or switching. Secondary objectives were to determine general health, disease status, pain status, productivity loss, patient compliance, and patient and physician preferences for the route of drug administration (oral or parenteral), along with prespecified interrelationships. In the scope of this study, investigators obtained the patient data from electronic or written patient records of the participating centres and entered these data on electronic case report forms. For some questionnaires, the data required were obtained directly from the patients via patient interviews and from medical records.

Data of the patients were archived in various ways in the study centres. One of the most commonly used data sources was the computer-based patient recording system.

Patient preferences were determined through a questionnaire, and physician preferences were determined according to the choice of treatment applied to the patient. Physicians decide their treatments considering patients’ general health status, socioeconomic and sociodemographic status and living conditions (urban/rural). Patients were evaluated at baseline (before the advanced RA therapy initiation or switch) and at 12 months, using the EuroQol Five-Dimensional Questionnaire, 3-level version (EQ-5D-3L; [27, 28]), the HAQ Disability Index (HAQ-DI; [29, 30]), DAS in 28 joints with ESR rate (DAS28-4[ESR]; [31, 32]), Compliance Questionnaire for Rheumatology (CQR-19; [33, 34]), Patient Global Assessment on a 100-mm visual analogue scale (PGA-VAS; [35]), Work Productivity and Activity Impairment Instrument (WPAI; [36–38]) and some additional questions, such as employment status, salary range, working hours per week for employed patients, loss of productive workdays within the last 3 months attributable to RA, number of days spent at home within the last 3 months attributable to RA flare, loss of productive workdays within the last 3 months attributable to RA flare requiring a hospital visit, loss of productive workdays within the last 3 months attributable to RA treatment administration, and duration of unemployment attributable to RA.

Higher scores indicate worse outcomes for HAQ-DI, DAS28-4(ESR) and WPAI and related questions, and better outcomes for EQ-5D-3L, PGA-VAS and CQR-19. Across all EQ-5D dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), the levels recognize ‘no problems, slight problems, moderate problems, severe problems, and unable to do/extreme’. Each dimension in the EQ-5D-3L has five response levels: no problems (level 1), slight problems (level 2), moderate problems (level 3), severe problems (level 4) and extreme problems (level 5).

Statistical analysis

A statistical calculation projected that 697 patients should be included in the study, with 95% power and ±3% accuracy to detect a significant relative increase of patients with low disease activity [estimated that 19% of patients at 6 months would present with a DAS28-4(ESR) score of <3.2]. Descriptive statistics are presented as the mean and s.d. or median (range) based on the distribution of data. Categorical variables are expressed as numbers and percentages. Normality was assessed with the Shapiro–Wilk test. Patients who completed questionnaires both at baseline and at 12 months were included in the analyses to assess change in questionnaire findings over time. The Wilcoxon signed rank and McNemar tests were used for repeated non-parametric comparisons (i.e. questionnaire scores and RoA preferences, respectively). Student’s paired t-test was used to compare baseline and 12-month ESR and CRP levels. The Mann–Whitney U test was used to compare patient preferences and physician prescriptions. To explore relationships between QoL and disease activity or compliance, correlation analyses were carried out for “EQ-5D-3L and DAS28-4(ESR)” and for “EQ-5D-3L and CQR-19” findings at baseline and 12 months, using Spearman’s rank correlation.

Binary logistic regression analysis was carried out to evaluate the effects of demographic and baseline disease characteristics on the preferred or prescribed administration routes at baseline. RoA was selected as the dependent variable, and age, gender, duration of RA, previous advanced RA treatment exposure, EQ-5D-3L, HAQ-DI, DAS28-4(ESR), PGA-VAS and CQR-19 were selected as independent variables. For statistical analysis, JAMOVI (v.1.0.8, retrieved from https://www.jamovi.org/) was used. In statistical analysis, the significance level (P-value) was considered as a two-sided value of 0.05.

Results

In total, 470 patients were evaluated. Eleven patients were excluded from the analysis set owing to violation of eligibility criteria (diagnoses other than RA), and 459 patients with moderately to severely active RA receiving advanced treatments were enrolled for the final analysis. Of these, 308 patients (67.1%) attended the study visit at 12 months. Patient demographics and baseline disease characteristics are shown in Table 1.

The majority of patients (76.0%) were female, and their mean age was 50.2 (12.0) years. At baseline, 351 patients (76.5%) were unemployed. Of the unemployed patients, 238 (67.8%) were stated being a housewife and 65 (18.5%) stated being retired. The mean duration of RA was 10.1 (7.9) years. HCQ, MTX and LEF were the most commonly prescribed medications for RA before study enrolment (48.2, 47.1 and 42.7%, respectively). At the beginning of the study, prescribed medications and the number of patients receiving them were as follows: tofacitinib 143 (31.2%); rituximab 69 (15.0%); tocilizumab 48 (10.5%); adalimumab 46 (10.0%); certolizumab pegol 44 (9.6%); etanercept 40 (8.7%); abatacept 40 (8.7%); golimumab 2 (4.6%); and infliximab 8 (1.7%). In addition to prescribed medications at the beginning of the study, the active medications used at 3, 6, 9 and
12 months of the study are given in Supplementary Table S1, available at Rheumatology Advances in Practice online. Advanced RA treatment was initiated in 358 patients (78.0%) who were previously receiving csDMARDs, whereas medication was changed in 101 (22.0%) patients who were previously treated with an advanced RA treatment. During the follow-up, advanced RA treatments were changed in 57 patients (12.0%) (Supplementary Table S2, available at Rheumatology Advances in Practice online). No patients died during the study period.

EQ-5D-3L and DAS28-4(ESR) scores changed significantly in favour of better outcomes over 12 months after advanced treatment initiation or switching ($P < 0.001$ for both; Table 2; Supplementary Tables S3 and S4, available at Rheumatology Advances in Practice online).

At study initiation, 246 patients (53.6%) preferred an oral route for the administration of advanced treatments, whereas 213 (46.4%) preferred a parenteral route. Patient preferences for the RoA were similar at 12 months (50% preferred oral or parenteral route; $P > 0.05$; Supplementary Table S5, available at Rheumatology Advances in Practice online).

**Table 1. Patient demographics, clinical characteristics and treatments**

| Characteristic | Enrolment ($n = 459$) | 12 months ($n = 308$) |
|---------------|-----------------------|-----------------------|
| Age, mean (s.d.), years | 50.2 (12.0) | |
| Female, $n$ (%) | 349 (76.0) | |
| Education level, $n$ (%) | | |
| Illiterate | 38 (8.3) | |
| Primary school graduate | 219 (47.7) | |
| Secondary school graduate | 49 (10.7) | |
| High-school graduate | 90 (19.6) | |
| University graduate | 59 (12.8) | |
| Postgraduate | 4 (0.9) | |
| Employed, $n$ (%) | 108 (23.5) | |
| Duration of RA, mean (s.d.), years | 10.1 (7.9) | |
| Previous advanced RA treatment, $n$ (%) | 358 (78.0) | |
| No | 358 (78.0) | |
| Yes | 101 (22.0) | |
| RA treatments, $n$ (%) | | |
| csDMARD | | |
| Tofacitinib (p.o. 5 mg twice a day) | 143 (31.2) | 93 (30.2) |
| bDMARD | | |
| TNFi | 46 (10.0) | 28 (9.1) |
| Adalimumab (s.c. 40 mg every 2 weeks) | 46 (10.0) | 28 (9.1) |
| Etanercept (s.c. 25 mg twice a week) | 40 (8.7) | 35 (11.4) |
| Golimumab (s.c. 50 mg every 4 weeks) | 21 (4.6) | 12 (3.9) |
| Infliximab (i.v. 5mg/kg 0, 2, 6 weeks) | 8 (1.7) | 5 (1.6) |
| Certolizumab (s.c. 200 or 400mg every 2 weeks) | 44 (9.6) | 30 (9.7) |
| Non-TNFi | | |
| Abatacept (i.v. 500, 750 or 1000 mg 0, 2, 4 weeks) | 40 (8.7) | 23 (7.5) |
| Rituximab (i.v. 1000 mg in 2 doses every 24 weeks) | 69 (15.0) | 53 (17.2) |
| Tocilizumab (i.v. 8 mg/kg every 4 weeks) | 48 (10.5) | 29 (9.4) |
| ESR, mean (s.d.), mm/h | 35.0 (22.2) | 23.6 (19.2) |
| CRP, mean (s.d.), mg/l | 20.3 (25.3) | 8.8 (12.9) |

$^a$ For duration of RA, $n = 458$.

$^b$ $P < 0.001$ for baseline vs 12-month levels.

bDMARD: biologic DMARD; CQR-19: Compliance Questionnaire for Rheumatology; csDMARD: conventional synthetic DMARD; DAS28-4(ESR): DAS in 28 joints with ESR; HAQ-DI: HAQ-Disability Index; TNFi: TNF inhibitor; tsDMARD: targeted synthetic DMARD.

**Table 2. Questionnaire scores at baseline and 12 months**

| Questionnaire | Baseline ($n = 308$) | 12 months ($n = 308$) | $P$-value |
|---------------|---------------------|----------------------|-----------|
| EQ-5D-3L | 0.52 (–0.59 to +1.00) | 0.73 (–0.24 to +1.00) | $<0.001$ |
| DAS28-4(ESR) | 5.05 (1.41–8.33) | 2.84 (0–7.26) | $<0.001$ |
| HAQ-DI | 0.90 (0–2.90) | 0.30 (0–2.50) | $<0.001$ |
| CQR-19 | 73.68 (17.5–96.5) | 68.42 (5.26–89.5) | $<0.001$ |
| PGA-VAS | 60.0 (0–100) | 30.0 (0–100) | $<0.001$ |
| WPAP $^a$ (%) | | | |
| Absenteem | 0 (0–100) | 0 (0–100) | 0.062 |
| Presenteeem | 50 (0–100) | 20 (10–90) | $<0.001$ |
| Overall work impairment | 60 (10–100) | 20 (10–100) | $<0.001$ |
| Activity impairment | 50 (10–100) | 20 (10–90) | $<0.001$ |

Values are shown as the median (range); $^a n = 63$ for WPAP completers.

CQR-19: Compliance Questionnaire for Rheumatology; DAS28-4(ESR): DAS in 28 joints with ESR; EQ-5D-3L: EuroQol Five-Dimensional Questionnaire 3-level version; HAQ-DI: HAQ-Disability Index; PGA-VAS: Patient Global Assessment on a 100-mm Visual Analogue Scale; WPAP: Work Productivity and Activity Impairment Instrument.
at *Rheumatology Advances in Practice* online). However, there was a significant difference between baseline patient preferences and physician prescriptions regarding the RoA, in that physicians favoured an advanced RA medication administered via a parenteral route more frequently (46.4% preferred oral route vs 68.6% preferred a parenteral route, *P* < 0.001). In 38.3% of cases, physicians prescribed advanced treatments with routes of administration that differed from patient preferences. Patient preferences for the RoA between advanced treatment-naive and treatment-experienced groups were similar at baseline (48.5% vs 55.0% for oral route, *P* = 0.361). When patients were classified according to administration routes of advanced therapies, baseline and 12-month questionnaire scores were similar for oral and parenteral route groups (*P* > 0.05 for all questionnaires; Table 3).

At baseline and 12 months, 35.3 and 8.1% of patients, respectively, reported extreme problems attributable to RA in the pain/discomfort domain of EQ-5D-3L, and 22.7 and 5.5% of patients, respectively reported extreme problems attributable to RA in the anxiety/depression domain. The proportions of patients indicating no problems related to RA increased by 25% or more within all EQ-5D-3L domains (Fig. 1; Supplementary Fig. S1, available at *Rheumatology Advances in Practice* online). A significant negative correlation was found between EQ-5D-3L and DAS28-4(ESR) scores at baseline (*n* = 459, *r* = −0.332, *P* < 0.001) and at 12 months (*n* = 308, *r* = −0.554, *P* < 0.001; Fig. 2).

For the RoA, both patient preferences and physician prescriptions were found to be independent of patient gender and age, duration of RA, previous exposure to advanced RA treatment, EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline (Table 4).

WPAI (except for absenteeism domain) scores changed significantly in favour of better outcomes over 12 months after advanced treatment initiation or switching (*P* < 0.001; Table 2). HAQ-DI and PGA-VAS scores also changed significantly in favour of better outcomes over 12 months after advanced treatment initiation or switching (*P* < 0.001 for both; Table 2).

CQR-19 scores decreased (73.7% at baseline vs. 68.4% at 12 months, *P* < 0.001; Table 2) and the proportion of patients with unsatisfactory compliance increased slightly. Significant correlations were also found at 12 months between CQR-19 and EQ-5D-3L and DAS28-4(ESR) scores (*n* = 308, *r* = 0.187, *P* < 0.001) but not at baseline.

Although an initial sample size of 697 patients was estimated to be needed, we were able to enrol 470 patients throughout the study period. However, in a post-study sensitivity analysis, it was observed that 56.2% of patients had a DAS28-4(ESR) score of <3.2 at 12 months. The precision of the study was calculated to be 5.5% at a significance level of α = 0.05. The analysis of additional questions was not found to be statistically significant (*P* > 0.05).

**Discussion**

In this longitudinal observational study, we observed that the oral route was more frequently preferred at the initiation of the advanced RA treatment, with a slight difference among the patients regarding the parenteral route. However, this

---

**Table 3. Questionnaire results at baseline and 12 months according to route of administration**

| Questionnaire | All patients, a median (min–max) (*n* = 308) | Oral route, median (min–max) (*n* = 94) | Parenteral route, median (min–max) (*n* = 214) | *P*-value (oral vs parenteral) |
|--------------|---------------------------------------------|----------------------------------------|---------------------------------------------|-----------------------------|
| EQ-5D-3L     |                                             |                                        |                                             |                             |
| Baseline     | 0.52 (0.59–1.00)                            | 0.52 (0.24–1.00)                       | 0.52 (0.59–1)                              | 0.698                       |
| 12 months    | 0.73 (0.24–1.00)                            | 0.72 (0.18–1.00)                       | 0.73 (0.24–1.00)                          | 0.962                       |
| DAS28-4(ESR) |                                             |                                        |                                             |                             |
| Baseline     | 5.05 (1.41–8.33)                            | 5.02 (2.09–7.83)                       | 5.05 (1.41–8.33)                          | 0.831                       |
| 12 months    | 2.84 (0–7.26)                               | 2.96 (0–7.26)                          | 2.81 (0.28–7.26)                          | 0.159                       |
| HAQ-DI       |                                             |                                        |                                             |                             |
| Baseline     | 0.90 (0–2.90)                               | 0.90 (0–2.70)                         | 0.95 (0–2.90)                             | 0.384                       |
| 12 months    | 0.30 (0–2.50)                               | 0.30 (0–2.35)                          | 0.30 (0–2.50)                             | 0.649                       |
| PGA-VAS      |                                             |                                        |                                             |                             |
| Baseline     | 60.0 (0–100)                                | 70.0 (5–100)                           | 60.0 (0–100)                              | 0.543                       |
| 12 months    | 30.0 (0–100)                                | 25.0 (0–80)                           | 30.0 (0–100)                              | 0.903                       |
| WPAI-Absenteeism (work time missed) | |                                        |                                             |                             |
| Baseline     | 0 (0–100)                                   | 0 (0–40)                              | 0 (0–100)                                 | 0.519                       |
| 12 months    | 0 (0–100)                                   | 0 (0–55)                              | 0 (0–100)                                 | 0.846                       |
| WPAI-Presence (impairment at work) | |                                        |                                             |                             |
| Baseline     | 50 (0–100)                                  | 60 (10–90)                            | 50 (0–100)                                | 0.211                       |
| 12 months    | 20 (10–90)                                  | 20 (10–80)                            | 20 (10–90)                                | 0.725                       |
| WPAI-Overall work impairment | |                                        |                                             |                             |
| Baseline     | 60 (10–100)                                 | 60 (10–90)                            | 60 (10–100)                               | 0.795                       |
| 12 months    | 20 (10–100)                                 | 20 (10–87)                            | 20 (10–100)                               | 0.684                       |
| WPAI-Activity impairment | |                                        |                                             |                             |
| Baseline     | 50 (10–100)                                 | 50 (10–100)                           | 50 (10–100)                               | 0.331                       |
| 12 months    | 20 (10–90)                                  | 20 (10–80)                            | 20 (10–90)                                | 0.916                       |

*a* For EQ-5D, DAS28-4(ESR), HAQ-DI, CQR-19 and PGA-VAS scores and WPAI percentages (except absenteeism), *P* < 0.001 for all patients from baseline to 12 months.

*b* For WPAI percentages, *n* = 63 for all, *n* = 22 for oral route and *n* = 41 for parenteral route.

CQR-19: Compliance Questionnaire for Rheumatology; DAS28-4(ESR): DAS in 28 joints with ESR; EQ-5D-3L: EuroQol Five-Dimensional Questionnaire 3-level version; HAQ-DI: HAQ-Disability Index; PGA-VAS: Patient Global Assessment on a 100-mm Visual Analogue Scale; WPAI: Work Productivity and Activity Impairment Instrument.
difference was lost at the end of 1 year. Contrary to the patients, the parenteral route was more frequently prescribed by the physicians, with a discordance rate of 38.3% at the initiation of the treatment. We also showed that the advanced RA treatment initiation or switching was associated with better QoL, general health status and disease activity over 12 months, with >50% of the patients reporting a low disease activity. These findings are in line with previous reports of improved patient-reported outcomes with use of advanced RA treatments [40, 41]. Likewise, a previous local study indicated better disease control and health status in RA patients who were on biological therapy when compared with patients who were eligible for biological therapy but not receiving it [25]. A weak to moderate negative correlation was found between EQ-5D-3L and DAS28-4(ESR) scores at baseline and 12 months, which is also similar to earlier reports [42, 43].

In our study, about half of the patients preferred an oral route for the administration of RA therapies at baseline and 12 months. Similar findings were reported by Louder et al. [14] in a simulated analysis and by Alten et al. [17] in a discrete choice experiment, reporting that 56 and 49% of patients, respectively, prefer an oral route for RA treatment. An international study also reported that 57% of RA patients preferred an oral route for their treatment. Speed and ease of administration were the most commonly stated reasons for the preference of an oral route [18]. In contrast, the preferences of physicians were somewhat different from those of the patients; in other words, we found a discrepancy between patient preferences and physician prescriptions regarding the RoA of advanced RA medication initiation or switching. More than two-thirds of the rheumatologists prescribed an advanced RA therapy to be administered via a parenteral route. The reason for the preference of a parenteral route by physicians might be a general belief in medical practice, stated as ‘The evident advantages of parenteral injection are the reliability and precision of dosage and the generally rapid onset

Figure 1. EuroQol 5-Dimensional Questionnaire patient responses per domain. EQ-5D-3L patient responses at (A) baseline (n = 459) and (B) 12 months (n = 308). EQ-5D-3L: EuroQol 5-Dimensional Questionnaire
of action of the drug’ [44] or a habit obtained during MTX prescription, because of its higher bioavailability and compliance in parenteral administration [45]. We did not identify any disease- or outcome-related factor associated with patient or physician choice for the RoA. Although evidence is lacking in the scientific literature, meeting patient preferences and shared decision-making between patients and physicians were estimated or expected to improve medication compliance [17, 18].

Medication compliance in RA has been evaluated in several studies with broadly varied methodology, using subjective reporting, validated surveys or drug monitoring to measure adherence. Validated survey results indicate compliance rates of 50–75% [46, 47], whereas stricter criteria point to compliance rates of 30–40% [48–50]. This finding was observed consistently, irrespective of the RoA. Although improved QoL and disease activity were associated with worse compliance at 12 months, the strength of correlations was very weak. The rate of non-compliance to advanced RA treatments has been reported to be 40% immediately after prescription of medication, and this rate did not differ across RoA and drugs [51]. Decreased medication compliance in inflammatory arthritis was also reported over a period of 6–12 months [52]. Observational studies examining compliance in RA have involved different drugs, patient groups and compliance measures, and differing results for factors associated with non-compliance have been published [46, 53]. These studies, however, consistently indicate a suboptimal compliance rate in RA patients, as our findings do, and some novel approaches have been suggested to improve patient education and compliance [53, 54]. However, the severity of RA is also proposed as a factor for medication adherence, and some patients might show non-adherent behaviour because they feel better after a period of the treatment [55].

Limitations

Although we failed to meet the prespecified sample size, the effect size-based proportion of patients with low disease activity [DAS28-4(ESR) score <3.2] turned out to be much higher than expected, and the margin of error within our study was found to be acceptable with the number of enrolled patients. The WPAI questionnaire and questions related to productivity were completed by a relatively low number of patients, because the employment ratio was low in our study cohort. Additionally, to help improve patient care, literacy might be a limitation for this study. We did not seek specifically to examine the relationship between patient and physician preferences for the RoA and medication compliance. This aspect, however, could be the objective of future studies considering the difference between the approaches of patients and health-care professionals for the RoA. The discordance between patient

Table 4. Binary logistic regression analyses of factors affecting the preference of patients and physicians for administration routes at baseline

| Independent variables | Patients (n = 459) | Physicians (n = 459) |
|-----------------------|------------------|---------------------|
| Gender                | 0.605            | 0.225               |
| Age                   | 0.804            | 0.342               |
| Duration of RA        | 0.379            | 0.075               |
| Previous advanced RA  | 0.247            | 0.602               |
| treatment exposure    |                  |                     |
| DAS28-4(ESR)          | 0.058            | 0.822               |
| HAQ-DI                | 0.672            | 0.070               |
| PGA-VAS               | 0.052            | 0.546               |
| EQ-5D-3L              | 0.354            | 0.735               |
| CQR-19*               | 0.204            | 0.583               |

*a Data were collected before prescription.

CQR-19: Compliance Questionnaire for Rheumatology; DAS28-4(ESR): DAS in 28 joints with ESR; EQ-5D-3L: EuroQol 5-Dimensional Questionnaire; HAQ-DI: HAQ Disability Index; PGA-VAS: Patient Global Assessment-Visual Analogue Scale.
and physician preferences should be evaluated further in future studies.

Conclusions
We observed that the choices of patients and physicians differed for the preferred RoA of advanced medications. The physicians more frequently preferred parenteral routes. The preference rate for the oral route by patients showed a slight decrease towards the end of 1 year. The initiation or switching of advanced RA treatments was associated with better QoL, control of disease activity, productivity and health status at 12 months. Compliance, however, worsened over time, regardless of the RoA. Dedicated future studies investigating the approach of patients and physicians for the preferred RoA of advanced RA medication might potentially contribute to management strategies for improved patient compliance.

Supplementary data
Supplementary data are available at Rheumatology Advances in Practice online.

Data availability statement
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

Funding
Pfizer has supported funding of this manuscript. Editorial/medical writing support was provided by Pleksus CRO Inc., and it was funded by Pfizer.

Disclosure statement: L.M.G., B.H., K.H., S.A., T.Y.C. and C.S.B. are employees of Pfizer Inc. L.M.G., T.Y.C., C.S.B. and S.Al. have stock and stock options for Pfizer Inc. U.K., A.T., A.S., A.A., B.Y., B.A., C.B., E.D., D.E., G.K., G.Y.C., H.D., M.E.T., M.C., N.Y., N.S., N.I., S.Y., S.S.K., O.K. and S.A.K. have received honoraria or educational/travel grants from Pfizer unlinked to this study. The author Servet Akar has no conflict of interest to declare.

Acknowledgements
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication.

References
1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130–6.
2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903–11.
3. Cross M, Smith E, Hoy D et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73:1316–22.
4. Akkoc N, Akar S. Epidemiology of rheumatoid arthritis in Turkey. Clin Rheumatol 2006;25:560–1.
5. Smolen JS, Landewé RBM, Bijlsma JWJ et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
6. Singh JA, Saag KG, Bridges SL Jr et al. American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26.
7. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26–34.
8. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23:S43–52.
9. Solomon DH, Karlson EW, Rimn EB et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
10. Sokka T, Kautiainen H, Pincus T et al.; the QUEST-RA study group. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42.
11. Thompson A. Practical aspects of therapeutic intervention in rheumatoid arthritis. J Rheumatol Suppl 2009;82:39–41.
12. Rupp I, Boschuijen HC, Dinant HJ, Jacobi CE, van den Bos GA. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol 2006;35:175–81.
13. McIntos IB, Combe B, Burmester G. Understanding the patient perspective – results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 2013;31:350–7.
14. Louder AM, Singh A, Saverno K et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 2016;9:84–93.
15. Kjeken I, Dagfinrud H, Mowinckel P et al. Rheumatology care: involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 2006;55:394–401.
16. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335–44.
17. Alten R, Krüger K, Rellecke J et al. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 2016;10:2217–28.
18. Taylor PC, Betteridge N, Brown TM et al. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence 2020;14:119–31.
19. Gibofsky A, Galloway J, Kekow J et al.; RA NarRAtive global advisory panel. Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys. Health Qual Life Outcomes 2018;16:211.
20. Bridges JFP, Hauber AB, Marshall D et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011;14:403–13.
21. Fraenkel L, Bogardus ST, Concato J et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004;63:1372–8.
22. Zhu B, Chang I, Qian L et al. RA medication preferences among U.S. patients in an online rheumatoid arthritis community. Arthritis Rheumatol 2016;68(Suppl 10):2238.
23. Choi IA, Kim JH, Hae Chang S et al. Patient perspectives on biological disease-modifying antirheumatic drugs: a multi-center study in Korea. Arch Rheumatol 2021;36:499–509.
24. Kumar K, Klocke R. Ethnicity in rheumatic disease. Clin Med (Lond) 2010;10:370–2.
25. Direskeneli H, Akkoç N, Bes C et al. Impact of rheumatoid arthritis in Turkey: a questionnaire study. Clin Exp Rheumatol 2014;32:477–83.
26. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/
European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–81.
27. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43.
28. Kaya N, Babadag K. Health related quality of life in patients with rheumatoid arthritis. Istanbul University FNHYO 2004;13:51–7.
29. Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992;5:119–29.
30. Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 2004;51:14–9.
31. Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989;32:531–7.
32. Sunar I, Yilmaz Tasdelen O, Garip Cimen Y, Bodur H. Translation and validation of the Turkish language version of the Rheumatoid Arthritis Disease Activity Index-5. Int J Rheum Dis 2017;20:2012–9.
33. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003;30:2469–75.
34. Inotai A, Rojkovich B, Fulop A et al. Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int 2012;32:963–9.
35. Strand V, Lee EB, Yazici Y et al. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: Post hoc analyses from two phase 3 trials. Clin Rheumatol 2018;37:2043–53.
36. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551–9.
37. Ariza-Arina R, Hernández-Cruz B, Carmona L et al.; Costs and Quality of Life in Rheumatoid Arthritis Study Group. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum 2006;55:751–6.
38. Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci 1968;57:357–78.
39. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther 2014;36:427–35.
40. van den Bent BJ, Zwikker HE, van den Ende CH. Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Rev Clin Immunol 2012;8:337–51.
41. Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 2013;43:18–28.
42. Park DC, Hertzog C, Leventhal H et al. Medication adherence in rheumatoid arthritis patients: older is wiser. J Am Geriatr Soc 1999;47:172–83.
43. Viller F, Guillemin F, Briancon S et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999;26:2114–22.
44. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int 2007;27:743–6.
45. Kan HJ, Dyaqilev K, Schulam P et al. Factors associated with physicians’ prescriptions for rheumatoid arthritis drugs not filled by patients. Arthritis Res Ther 2018;20:79.
46. de Klerk E, van der Heijde D, Landewé R et al. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003;30:44–54.
47. Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumatol 2015;10:345–56.
48. Joplin S, van der Zwan R, Joshua F, Wong PKK. Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015;2015:150658.
49. Oshotse C, Zullig LL, Bosworth HB, Tu P, Lin C. Self-efficacy and adherence behaviors in rheumatoid arthritis patients. Prev Chronic Dis 2018;15:E127.